Plasma fibrinogen level is an important determinant of prolonged euglobulin clot lysis time in hemodialysis patients

被引:5
作者
Borawski, J [1 ]
Mysliwiec, M [1 ]
机构
[1] Med Acad Bialystok, Dept Nephrol & Internal Med, PL-15540 Bialystok, Poland
关键词
euglobulin clot lysis time; fibrinogen; hemodialysis;
D O I
10.1177/107602960100700408
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The euglobulin clot lysis time (ECLT), a traditional measure of plasminogen activation. directly depends on plasma fibrinogen (FBG) level. This fact was neglected in studies concluding that prolonged ECLT in chronic hemodialysis (HD) patients pointed exclusively to impaired fibrinolysis. We studied the relations between ECLT and plasma FBG levels in HD patients in relation to certain hepatic and inflammatory markers. Median ECLT of 320 minutes (range, 150 to 620 minutes) and plasma FBG of 306 mg/dL (range, 171 to 553 mg/dL) were higher in 75 HD patients than in 60 healthy controls (Mann-Whitney p < 0.0001). There were positive associations between these parameters both in the patients (Spearman p = 0.273, p = 0.018) and the controls (p = 0.672, p < 0.0001). The FBG-corrected ECLT (plasma FBG/ECLT) (in mg/[min x dL]) in the patients (0.92 [range, 0.47 to 2.43]) was not different (p = 0.065) from that in the controls (1.08 [0.58 to 1.67]). In the patients, serum alanine aminotransferase inversely correlated with ECLT (p = -0.306, p = 0.008) and FBG (p = -0.310, p = 0.007), whereas serum C-reactive protein was associated positively with these variables (p = 0.383, p = 0.0007; p = 0.477, p < 0.0001, respectively). The FBG-corrected ECLT was not related to either marker. In conclusion, increased plasma FBG level, a continuum between liver dysfunction and stimulation by chronic inflammation, is an important determinant of prolonged ECLT in HD patients. The FBG-corrected ECLT value suggests that baseline activation of fibrinolysis is normal in these patients, and that this simple index could be useful in its laboratory assessment.
引用
收藏
页码:296 / 299
页数:4
相关论文
共 12 条
[1]  
BOCKENSTEDT PL, 1994, THROMBOSIS HEMORRHAG, P455
[2]   HEMOSTASIS VARIABLES IN TYPE-I DIABETIC-PATIENTS WITHOUT DEMONSTRABLE VASCULAR COMPLICATIONS [J].
ELKHAWAND, C ;
JAMART, J ;
DONCKIER, J ;
CHATELAIN, B ;
LAVENNE, E ;
MORIAU, M ;
BUYSSCHAERT, M .
DIABETES CARE, 1993, 16 (08) :1137-1145
[3]  
HAVERKATE F, 1995, THROMB HAEMOSTASIS, V73, P561
[4]  
HONG SY, 1993, NEPHRON, V63, P188
[5]   HEMOSTATIC CHANGES IN HEART-TRANSPLANT RECIPIENTS AND THEIR RELATIONSHIP TO ACCELERATED CORONARY SCLEROSIS [J].
HUNT, BJ ;
SEGAL, H ;
YACOUB, M .
TRANSPLANTATION, 1993, 55 (02) :309-315
[6]  
ITO T, 1972, CLIN CHIM ACTA, V36, P145
[7]  
LOWE GDO, 1980, BLOOD COAGULATION HA, P222
[8]   Hemostasis, platelet function and serotonin in acute and chronic renal failure [J].
Malyszko, J ;
Malyszko, JS ;
Pawlak, D ;
Pawlak, K ;
Buczko, W ;
Mysliwiec, M .
THROMBOSIS RESEARCH, 1996, 83 (05) :351-361
[9]   The coagulo-lytic system and endothelial function in cyclosporine-treated kidney allograft recipient [J].
Malyszko, J ;
Malyszko, JS ;
Pawlak, K ;
Mysliwiec, M .
TRANSPLANTATION, 1996, 62 (06) :828-830
[10]   A STUDY OF PLATELET FUNCTIONS, SOME HEMOSTATIC AND FIBRINOLYTIC PARAMETERS IN RELATION TO SEROTONIN IN HEMODIALYZED PATIENTS UNDER ERYTHROPOIETIN THERAPY [J].
MALYSZKO, J ;
MALYSZKO, JS ;
BORAWSKI, J ;
RYDZEWSKI, A ;
KALINOWSKI, M ;
AZZADIN, A ;
MYSLIWIEC, M ;
BUCZKO, W .
THROMBOSIS RESEARCH, 1995, 77 (02) :133-143